Mechanism of Inflammation in Murine Eosinophilic Myocarditis Produced by Adoptive Transfer with Ovalbumin ChallengeHirasawa M. · Ito Y. · Shibata M.-A. · Otsuki Y.
Department of Anatomy and Biology, Osaka Medical College, Osaka, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Interleukin (IL)-5, RANTES and CC chemokine receptor 3 (CCR3) are essential for induction of eosinophil recruitment in organs, but the precise pathogenesis of eosinophilic myocarditis is still unclear. We investigated the relationships between these cytokines and receptors in the development of inflammation in murine myocarditis produced by adoptive transfer, with reference to eosinophil infiltration and signal transduction. Methods: The splenocytes from male donor DBA/2 mice were separated after ovalbumin (OVA) sensitization. These cells had a CD4/CD8 ratio of approximately 3.0. Cells (2.0 × 107) were individually transfused to recipient adoptive male DBA/2 mice, and OVA challenge was performed serially. The heart and spleen of the recipient were analyzed to determine the kinetics of IL-5, RANTES, CCR3 and eosinophil production with simultaneous determination of Janus kinase 3 (JAK3) mRNA. Results: Approximately 85% of recipient mice developed myocarditis; 35% had recognizable cell infiltration in the left ventricular endocardium, an effect which was absent in control mice. Eosinophilic myocarditis was usually associated with animals having several degenerative changes in myocardial cells, and IL-5, RANTES and CCR3 expressions were usually present in these eosinophils (p < 0.05). CCR3 and JAK3 mRNAs were detected in the spleens and hearts of recipient animals providing histological evidence for kinetics related to eosinophil infiltration. Conclusion: The murine model of adoptive transferred myocarditis is suitable for studying the mechanism of eosinophilic myocarditis. A unique pathogenesis of this disorder may be controlled by the synergism of CD4 dominancy in the donor and JAK-STAT signaling in the recipient, which may cause recruitment of eosinophils into heart lesions.
© 2007 S. Karger AG, Basel
- Burke AP, Saenger J, Mullick F, Virmani R: Hypersensitivity myocarditis. Arch Pathol Lab Med 1991;115:764–769.
- Renaldini E, Spandrio S, Cerudelli B, Affatato A, Balestrieri P: Cardiac involvement in Churg-Strauss syndrome: a follow-up of three cases. Eur Heart J 1993;14:1712–1716.
- Bocchi EA, Bellotti G, Mocelin AO, Uip D, Bacal F, Higuchi ML, Amato-Neto V, Fiorelli A, Stolf NA, Jatene AD, Pileggi F: Heart transplantation for chronic Chagas’ heart disease. Ann Thorac Surg 1996;61:1727–1733.
Hirota Y: Restrictive cardiomyopathy, cardiac amyloidosis, and hypereosinophilic heart disease; in Abelmann WH (ed): Atlas of Heart Diseases. Cardiomyopathies, Myocarditis, and Pericardial Disease. Philadelphia, Current Medicine, 1994, pp 5.1–5.15.
- Tai PC, Ackerman SJ, Spry CJF, Dunnette S, Olsen EG, Gleich GJ: Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1987;i:643–647.
- Spry CJF, Tai PC: Studies on blood eosinophils. Clin Exp Immunol 1976;24:423–434.
- Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Granick HR, Bjornson BH: The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations (NIH conference). Ann Intern Med 1982;97:78–92.
- Trueb RM, Lubbe J, Torricelli R, Panizzon RG, Wuthrich B, Burg G: Eosinophilic myositis with eosinophilic cellulitis-like skin lesions. Association with increased serum levels of eosinophil cationic protein and interleukin-5. Arch Dermatol 1997;133:203–206.
- Ishida Y, Hayashi M, Higaki A, Matsumoto K, Iikura Y, Ishikawa J, Kida K: Hypereosinophilic syndrome with generalized myasthenia gravis. J Pediatr 1996;128:369–372.
- Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJM: Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J Immunol 1998;161:6215–6222.
- Nakajima H, Nakao A, Kumano K, Yamamoto H, Iwamoto I: Systemic T-helper 2 cell activation is not sufficient for antigen-induced eosinophil recruitment into the airways. Int Arch Allergy Immunol 2000;122(suppl 1):20–24. DOI: 1018-2438/00/ 1225–0020.
- Kasai M, Kurasawa K, Nakajima H, Iwamoto I: T cell vaccination eliminates antigen-specific T cells and prevents antigen-induced eosinophil recruitment into the tissue. Int Arch Allergy Immunol 2001;125(suppl 1): 59–66. DOI: 1018-2438/01/1255–0059.
- Kon OM, Kay AB: T cells and chronic asthma. Int Arch Allergy Immunol 1999;118:133–135. DOI: 1018-2438/99/1184–0133.
- Velazquez JR, Lacy P, Moqbel R: Replenishment of RANTES mRNA expression in activated eosinophils from atopic asthmatics. Immunology 2000;99:591–599.
- Yamada K, Eliott WM, Brattsand R, Valeur A, Hogg JC, Hayashi S: Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation. J Allergy Clin Immunol 2002;109:35–42. DOI: 10.1067/mai.2002.120525.
- Southam DS, Widmer N, Ellis R, Hirota JA, Inman MD, Sehmi R: Increased eosinophil-lineage committed progenitors in the lung of allergen-challenged mice. J Allergy Clin Immunol 2005;115:95–102. DOI: 10.1016/j-jaci.2004.09.022.
- Lacy P, Weller PF, Moqbel R: A report from the International Eosinophil Society: eosinophils in a tug of war. J Allergy Clin Immunol 2001;108:895–900. DOI: 10.1067/mai. 2001.120194.
- Ishimitsu R, Nishimura H, Yajima T, Watase T, Kawauchi H, Yoshikai Y: Overexpression of IL-15 in vivo enhances Tc1 response, which inhibits allergic inflammation in a murine model of asthma. J Immunol 2001;166:1991–2001. DOI: 0022-1767/01/$02.00
- Maisel A, Cesario D, Baird S, Rehman J, Haghighi P, Carter S: Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction. Circ Res 1998;82:458–463.
- Shioji K, Yuan Z, Kita T, Kishimoto C: Immunoglobulin treatment suppressed adoptively transferred autoimmune myocarditis in severe combined immunodeficient mice. Am J Physiol Heart Circ Physiol 2004;287:H2619–H2625. DOI: 10.1152/ajpheart.01130, 2003.
- Van-Vleet JF, Ferrans VJ: Ultrastructural changes in inherited cardiac calcinosis of DBA/2 mice. Am J Vet Res 1987;48:255–261.
- Yamate J, Tajima M, Maruyama Y, Kudow S: Observations on soft tissue calcification in DBA/2NCrj mice in comparison with CRJ:CD-1 mice. Lab Anim 1987;21:289–298.
- Kruppenbacher JP, Arnold G, Mertens T, Fischer A, Zimmermann J, Eggers HJ: Outbred mice infected by an encephalomyocarditis virus variant: a model for studying chronic viral heart disease. Virchows Arch A Pathol Anat Histopathol 1993;422:405–413.
- Kuan AP, Chamberlain W, Malkiel S, Lieu HD, Factor SM, Diamond B, Kotzin BL: Genetic control of autoimmune myocarditis mediated by myosin-specific antibodies. Immunogenetics 1999;49:79–85.
Kitaura Y, Morita H, Deguchi H, Kotaka M, Kawamura K: Histopathologic and hemodynamic study of the heart in spontaneously developed perimyocarditis in DBA/2 mice. International Symposium on Cardiomyopathy and Myocarditis, Tokyo, Japan, December 12–15 (abstract). Heart Vessels 1984;(suppl 1):311.
- Hirasawa M, Kitaura Y, Deguchi H, Ukimura A, Kawamura K: Spontaneous myocarditis in DBA/2 mice. Light microscopic study with transmission and analytical electron microscopic studies. Virchows Arch 1998;432:461–468.
- Hirasawa M, Deguchi H, Ukimura A, Kitaura Y: Immunologic interaction between infiltrating eosinophils and T lymphocytes in murine spontaneous eosinophilic myocarditis. Int Arch Allergy Immunol 2003;130:73–81. DOI: 10.1159/000068371.
Hirasawa M, Deguchi H, Kitaura Y: Mutual relation between local infiltrative eosinophils and T cell subsets of experimental (spontaneous and OVA-challenged) eosinophilic heart disease in mice (abstract). Int Arch Allergy Immunol 2003;131(suppl 1):47. DOI: 10.1159/000070481.
Hirasawa M, Deguchi H, Kitaura Y: Expression of interleukin-5 and RANTES in the heart in murine ovalbumin-challenged myocarditis (abstract). Int Arch Allergy Immunol 2004;134(suppl 1):45. DOI: 10.1159/ 000077792.
- Pecaut MJ, Nelson GA, Peters LL, Kostenuik PJ, Bateman TA, Morony S, Stodieck LS, Lacey DL, Simske SJ, Gridley DS: Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in C57BL/6 mouse. 1. Immune population distributions. J Appl Physiol 2003;94:2085–2094. DOI: 10.1152/japplphysiol.01052. 2002.
- Jurjus AR, Khoury NN, Reimund JM: Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004;50:81–92. DOI: 10.1016/j-vascn. 2003.12.002.
- Grabie N, Hsieh DT, Buono C, Westrich JR, Allen JA, Pang H, Stavrakis G, Lichtman AH: Neutrophils sustain pathogenic CD8+ T cell responses in the heart. Am J Pathol 2003;163:2413–2420.
- Forssmann U, Uguccioni M, Loetscher P, Dahinden CA, Langen H, Thelen M, Baggiolini M: Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997;185:2171–2176. DOI: 0022–1007/ 97/06/2171/06$2.00.
- Moser B, Wolf M, Walz A, Loetscher P: Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004;25:75–84. DOI: 10.1016/j.it.2003.12.005.
- Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, Parish C: Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197:387–393. DOI: 10.1084/jem.20021683.
- Gurniak CB, Berg LJ: Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood 1996;87:3151–3160.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.